Pharmaceutical Executive November 22, 2023
Leuchter discusses FDA’s new pilot program.
The FDA recently launched a new pilot program to encourage the development of new drugs for rare diseases. Dr. Bruce Leuchter, CEO of Neurvati, spoke with Pharmaceutical Executive about this new program and the impact it could have on the industry.
Bruce Leuchter: We’re most interested in actionable opportunities that meet a certain threshold for likely success in subsequent development. We have the benefit of stepping back and looking across their assignments and, as the case may be, rare disease in neuroscience is a pretty relevant topic. We find ourselves organizing around our communities where the sorts of things that have been put forward in the single trial path by FDA are incredibly useful...
Today's Sponsors
Today's Sponsor